000756.SHE Shandong Xinhua Pharmaceutical Co Ltd
- Market cap
- CNY 8.52B
- P/E
- 37.1x
- P/B
- 1.60x
- ROE
- 4.9%
- Dividend yield
- 2.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000756.SHE undervalued?
Graham number000756.SHE trades 62.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Xinhua Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shandong Xinhua Pharmaceutical Co Ltd yet.
Shandong Xinhua Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generi…
Full company profileShandong Xinhua Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Xinhua Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.01B | 4.52B | 5.24B | 5.61B | 6.01B | 6.56B | 7.50B | 8.10B | 8.47B | 8.74B | 8.08B |
| Gross Profit | 976M | 1.25B | 1.53B | 1.79B | 1.76B | 1.74B | 1.99B | 2.32B | 1.99B | 1.63B | 1.51B |
| Operating Income | 152M | 282M | 345M | 387M | 422M | 426M | 477M | 535M | 534M | 346M | 410M |
| EBITDA | 447M | 583M | 667M | 734M | 843M | 840M | 952M | 1.03B | 1.05B | 346M | 318M |
| Net Income | 122M | 210M | 255M | 300M | 325M | 349M | 411M | 497M | 470M | 290M | 260M |
| EPS | 0.21 | 0.35 | 0.41 | 0.48 | 0.52 | 0.56 | 0.61 | 0.72 | 0.68 | 0.42 | 0.37 |
| Balance Sheet | |||||||||||
| Total Assets | 4.72B | 5.27B | 5.92B | 6.44B | 7.09B | 7.33B | 8.27B | 8.29B | 9.02B | 9.19B | 8.81B |
| Total Liabilities | 2.64B | 2.69B | 3.12B | 3.33B | 3.70B | 3.68B | 3.92B | 3.51B | 3.80B | 3.73B | 3.22B |
| Shareholders' Equity | 1.99B | 2.48B | 2.69B | 2.97B | 3.22B | 3.47B | 4.13B | 4.55B | 4.99B | 5.21B | 5.34B |
| Cash & Short-term Investments | 561M | 731M | 778M | 690M | 856M | 745M | 1.16B | 918M | 1.25B | 1.40B | 1.19B |
| Total Debt | 1.35B | 1.17B | 1.36B | 1.48B | 1.09B | 1.04B | 1.38B | 1.87B | 1.35B | 1.31B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 439M | 390M | 345M | 348M | 420M | 259M | 758M | 265M | 368M | 534M | - |
| Capital Expenditure | 227M | 261M | 386M | 367M | 280M | 249M | 245M | 325M | 212M | 116M | 94.5M |
| Free Cash Flow | 212M | 129M | -41.4M | -18.2M | 140M | 9.89M | 513M | -59.9M | 155M | 418M | 148M |
| Ratios | |||||||||||
| ROE | 6.1% | 8.5% | 9.5% | 10.1% | 10.1% | 10.1% | 10.0% | 10.9% | 9.4% | 5.6% | 4.9% |
| ROA | 2.6% | 4.0% | 4.3% | 4.7% | 4.6% | 4.8% | 5.0% | 6.0% | 5.2% | 3.2% | 3.0% |
| Net Profit Margin | 3.0% | 4.6% | 4.9% | 5.4% | 5.4% | 5.3% | 5.5% | 6.1% | 5.6% | 3.3% | 3.2% |
| Debt to Equity | 0.68x | 0.47x | 0.51x | 0.50x | 0.34x | 0.30x | 0.34x | 0.41x | 0.27x | 0.25x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Xinhua Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.46%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 72.4%
- Ex-dividend date
- Jul 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 210M | 0.30 | 72.4% |
| 2024 | CNY 226M | 0.33 | 48.1% |
| 2023 | CNY 176M | 0.26 | 35.4% |
| 2022 | CNY 100M | 0.15 | 24.4% |
| 2021 | CNY 94.1M | 0.15 | 27.0% |
| 2020 | CNY 74.6M | 0.12 | 23.0% |
| 2019 | CNY 62.2M | 0.10 | 20.7% |
| 2018 | CNY 89.8M | 0.14 | 35.2% |
| 2017 | CNY 54.4M | 0.09 | 26.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 27, 2018.
Who owns Shandong Xinhua Pharmaceutical Co Ltd
- Insiders 49.84%
- Institutions 0.45%
- Public & others 49.71%
- Shares outstanding 502M
- Free float 467M
Shandong Xinhua Pharmaceutical Co Ltd company profile
- Company name
- Shandong Xinhua Pharmaceutical Co Ltd
- Ticker
- 000756.SHE
- ISIN
- CNE000000BG1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,240
- Fiscal year end
- December
- Address
- No. 1 Lutai Avenue, Zibo, China, 255086
- Phone
- 86 53 3219 5636
- Website
- xhzy.com
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate and housing leasing activities; certification and import and export business; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. The company was founded in 1943 and is based in Zibo, the People's Republic of China.
Shandong Xinhua Pharmaceutical Co Ltd management
8- Mr. Tongqing HeExecutive Chairman · born 1970
- Mr. Wenhui XuGM & Executive Director · born 1977
- Mr. Ning HouCFO & Executive Director · born 1974
- Mr. Changsheng WeiDeputy GM & Manager of the Administrative Personnel Department · born 1971
- Mr. Xuesong LiuDeputy General Manager · born 1985
- Mr. Zuxing KouDeputy General Manager · born 1982
- Mr. Changqiu CaoCompany Secretary · born 1970
- Mr. Xiaohong HeHead of Accounting Department